ACR Presents CPT Code Changes for Emerging Imaging Tools
ACR and partner societies proposed CPT updates for quantitative CT and AI risk scoring, but the AMA panel requested resubmission for refinement.
Read more3D imaging is not routinely performed and requires added resources, including specialized software, trained personnel and physician input.
ACR® recently asked Blue Cross Blue Shield of North Carolina (BCBS NC) to reconsider its reimbursement policy that classifies 3D rendering services (CPT® codes 76376 and 76377) as integral to primary imaging procedures and therefore not eligible for separate reimbursement. The College emphasized 3D imaging is not routinely performed and requires additional resources, including specialized software, trained personnel and physician input. These services provide enhanced diagnostic value, particularly in complex cases and surgical planning and are not automatically or routinely done as part of standard imaging interpretation.
3D rendering services consume additional resources beyond what is accounted for in the primary imaging CPT code. The existence of distinct CPT codes for 3D rendering confirms their status as standalone procedures. These codes have specific documentation and reporting guidelines and are not universally bundled with other imaging services.
ACR strongly disagrees with BCBS NC’s bundling policy and asked the insurer to reconsider to be in alignment with CMS’ policies and industry standards.
If you have questions about the BCBS NC policy and the College’s response, contact Katie Keysor, ACR Senior Director of Economic Policy.
ACR Presents CPT Code Changes for Emerging Imaging Tools
ACR and partner societies proposed CPT updates for quantitative CT and AI risk scoring, but the AMA panel requested resubmission for refinement.
Read moreContact Your Lawmakers to Cosponsor the ROOT Act
ACR urges lawmakers to cosponsor the ROOT Act to streamline imaging AUC (PAMA), boost patient safety, and cut Medicare costs.
Read moreBill to Boost Women’s Lung Cancer Research
House passes H.R. 2319 to expand women’s lung cancer research, screening and prevention; Senate action is still needed.
Read more